2xfb Citations

Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography.

Nature 468 709-12 (2010)
Related entries: 1z8y, 2xfc, 3n40, 3n41, 3n42, 3n43, 3n44

Cited: 384 times
EuropePMC logo PMID: 21124458

Abstract

Chikungunya virus (CHIKV) is an emerging mosquito-borne alphavirus that has caused widespread outbreaks of debilitating human disease in the past five years. CHIKV invasion of susceptible cells is mediated by two viral glycoproteins, E1 and E2, which carry the main antigenic determinants and form an icosahedral shell at the virion surface. Glycoprotein E2, derived from furin cleavage of the p62 precursor into E3 and E2, is responsible for receptor binding, and E1 for membrane fusion. In the context of a concerted multidisciplinary effort to understand the biology of CHIKV, here we report the crystal structures of the precursor p62-E1 heterodimer and of the mature E3-E2-E1 glycoprotein complexes. The resulting atomic models allow the synthesis of a wealth of genetic, biochemical, immunological and electron microscopy data accumulated over the years on alphaviruses in general. This combination yields a detailed picture of the functional architecture of the 25 MDa alphavirus surface glycoprotein shell. Together with the accompanying report on the structure of the Sindbis virus E2-E1 heterodimer at acidic pH (ref. 3), this work also provides new insight into the acid-triggered conformational change on the virus particle and its inbuilt inhibition mechanism in the immature complex.

Reviews - 2xfb mentioned but not cited (1)

  1. An alternative pathway for alphavirus entry. Kononchik JP, Hernandez R, Brown DT. Virol. J. 8 304 (2011)

Articles - 2xfb mentioned but not cited (14)

  1. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MK, Smit JM, Fremont DH, Pierson TC, Heise MT, Diamond MS. PLoS Pathog. 9 e1003312 (2013)
  2. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. Kam YW, Lum FM, Teo TH, Lee WW, Simarmata D, Harjanto S, Chua CL, Chan YF, Wee JK, Chow A, Lin RT, Leo YS, Le Grand R, Sam IC, Tong JC, Roques P, Wiesmüller KH, Rénia L, Rötzschke O, Ng LF. EMBO Mol Med 4 330-343 (2012)
  3. Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. Kam YW, Lee WW, Simarmata D, Harjanto S, Teng TS, Tolou H, Chow A, Lin RT, Leo YS, Rénia L, Ng LF. J. Virol. 86 13005-13015 (2012)
  4. Genome-scale phylogeny of the alphavirus genus suggests a marine origin. Forrester NL, Palacios G, Tesh RB, Savji N, Guzman H, Sherman M, Weaver SC, Lipkin WI. J. Virol. 86 2729-2738 (2012)
  5. A single-amino-acid polymorphism in Chikungunya virus E2 glycoprotein influences glycosaminoglycan utilization. Silva LA, Khomandiak S, Ashbrook AW, Weller R, Heise MT, Morrison TE, Dermody TS. J. Virol. 88 2385-2397 (2014)
  6. Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. Gardner CL, Hritz J, Sun C, Vanlandingham DL, Song TY, Ghedin E, Higgs S, Klimstra WB, Ryman KD. PLoS Negl Trop Dis 8 e2719 (2014)
  7. Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response. Her Z, Teng TS, Tan JJ, Teo TH, Kam YW, Lum FM, Lee WW, Gabriel C, Melchiotti R, Andiappan AK, Lulla V, Lulla A, Win MK, Chow A, Biswas SK, Leo YS, Lecuit M, Merits A, Rénia L, Ng LF. EMBO Mol Med 7 24-41 (2015)
  8. The structure of barmah forest virus as revealed by cryo-electron microscopy at a 6-angstrom resolution has detailed transmembrane protein architecture and interactions. Kostyuchenko VA, Jakana J, Liu X, Haddow AD, Aung M, Weaver SC, Chiu W, Lok SM. J. Virol. 85 9327-9333 (2011)
  9. Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis. Jin J, Liss NM, Chen DH, Liao M, Fox JM, Shimak RM, Fong RH, Chafets D, Bakkour S, Keating S, Fomin ME, Muench MO, Sherman MB, Doranz BJ, Diamond MS, Simmons G. Cell Rep 13 2553-2564 (2015)
  10. Structural plasticity of the Semliki Forest virus glycome upon interspecies transmission. Crispin M, Harvey DJ, Bitto D, Bonomelli C, Edgeworth M, Scrivens JH, Huiskonen JT, Bowden TA. J. Proteome Res. 13 1702-1712 (2014)
  11. Natural variation in the heparan sulfate binding domain of the eastern equine encephalitis virus E2 glycoprotein alters interactions with cell surfaces and virulence in mice. Gardner CL, Choi-Nurvitadhi J, Sun C, Bayer A, Hritz J, Ryman KD, Klimstra WB. J. Virol. 87 8582-8590 (2013)
  12. Emerging Chikungunya Virus Variants at the E1-E1 Interglycoprotein Spike Interface Impact Virus Attachment and Inflammation. Rangel MV, McAllister N, Dancel-Manning K, Noval MG, Silva LA, Stapleford KA. J Virol 96 e0158621 (2022)
  13. Conformational changes in Chikungunya virus E2 protein upon heparan sulfate receptor binding explain mechanism of E2-E1 dissociation during viral entry. Sahoo B, Chowdary TK. Biosci. Rep. 39 (2019)
  14. Early Genomic Surveillance and Phylogeographic Analysis of Getah Virus, a Reemerging Arbovirus, in Livestock in China. Zhao J, Dellicour S, Yan Z, Veit M, Gill MS, He WT, Zhai X, Ji X, Suchard MA, Lemey P, Su S. J Virol 97 e0109122 (2023)


Reviews citing this publication (94)

  1. Chikungunya virus and the global spread of a mosquito-borne disease. Weaver SC, Lecuit M. N. Engl. J. Med. 372 1231-1239 (2015)
  2. Allostery and the Monod-Wyman-Changeux model after 50 years. Changeux JP. Annu Rev Biophys 41 103-133 (2012)
  3. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Thiberville SD, Moyen N, Dupuis-Maguiraga L, Nougairede A, Gould EA, Roques P, de Lamballerie X. Antiviral Res. 99 345-370 (2013)
  4. Construction and characterization of virus-like particles: a review. Zeltins A. Mol. Biotechnol. 53 92-107 (2013)
  5. Structure unifies the viral universe. Abrescia NG, Bamford DH, Grimes JM, Stuart DI. Annu. Rev. Biochem. 81 795-822 (2012)
  6. Viral membrane fusion. Harrison SC. Virology 479-480 498-507 (2015)
  7. Chikungunya: Evolutionary history and recent epidemic spread. Weaver SC, Forrester NL. Antiviral Res. 120 32-39 (2015)
  8. Virus assembly, allostery and antivirals. Zlotnick A, Mukhopadhyay S. Trends Microbiol 19 14-23 (2011)
  9. Factors shaping the adaptive landscape for arboviruses: implications for the emergence of disease. Coffey LL, Forrester N, Tsetsarkin K, Vasilakis N, Weaver SC. Future Microbiol 8 155-176 (2013)
  10. Cell entry of enveloped viruses. Plemper RK. Curr Opin Virol 1 92-100 (2011)
  11. Class II enveloped viruses. Vaney MC, Rey FA. Cell. Microbiol. 13 1451-1459 (2011)
  12. Early Events in Chikungunya Virus Infection-From Virus Cell Binding to Membrane Fusion. van Duijl-Richter MK, Hoornweg TE, Rodenhuis-Zybert IA, Smit JM. Viruses 7 3647-3674 (2015)
  13. Global expansion of chikungunya virus: mapping the 64-year history. Wahid B, Ali A, Rafique S, Idrees M. Int. J. Infect. Dis. 58 69-76 (2017)
  14. Chikungunya, a paradigm of neglected tropical disease that emerged to be a new health global risk. Rougeron V, Sam IC, Caron M, Nkoghe D, Leroy E, Roques P. J. Clin. Virol. 64 144-152 (2015)
  15. Chikungunya virus: an update on antiviral development and challenges. Kaur P, Chu JJ. Drug Discov. Today 18 969-983 (2013)
  16. Principles of virus structural organization. Prasad BV, Schmid MF. Adv. Exp. Med. Biol. 726 17-47 (2012)
  17. Common Features of Enveloped Viruses and Implications for Immunogen Design for Next-Generation Vaccines. Rey FA, Lok SM. Cell 172 1319-1334 (2018)
  18. How to get out: ssRNA enveloped viruses and membrane fission. Weissenhorn W, Poudevigne E, Effantin G, Bassereau P. Curr Opin Virol 3 159-167 (2013)
  19. Structure of viruses: a short history. Rossmann MG. Q. Rev. Biophys. 46 133-180 (2013)
  20. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. Silva LA, Dermody TS. J. Clin. Invest. 127 737-749 (2017)
  21. Herpesvirus gB: A Finely Tuned Fusion Machine. Cooper RS, Heldwein EE. Viruses 7 6552-6569 (2015)
  22. Updates on chikungunya epidemiology, clinical disease, and diagnostics. Sam IC, Kümmerer BM, Chan YF, Roques P, Drosten C, AbuBakar S. Vector Borne Zoonotic Dis. 15 223-230 (2015)
  23. Relating structure to evolution in class II viral membrane fusion proteins. Modis Y. Curr Opin Virol 5 34-41 (2014)
  24. Cellular and molecular mechanisms of chikungunya pathogenesis. Lum FM, Ng LF. Antiviral Res. 120 165-174 (2015)
  25. Viral precursor polyproteins: keys of regulation from replication to maturation. Yost SA, Marcotrigiano J. Curr Opin Virol 3 137-142 (2013)
  26. A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development. de Lima Cavalcanti TYV, Pereira MR, de Paula SO, Franca RFO. Viruses 14 969 (2022)
  27. Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. Sabahi A, Uprichard SL, Wimley WC, Dash S, Garry RF. J. Virol. 88 10280-10288 (2014)
  28. A molecular understanding of alphavirus entry. Holmes AC, Basore K, Fremont DH, Diamond MS. PLoS Pathog 16 e1008876 (2020)
  29. Alphavirus structure: activation for entry at the target cell surface. Vaney MC, Duquerroy S, Rey FA. Curr Opin Virol 3 151-158 (2013)
  30. Class II fusion proteins. Modis Y. Adv Exp Med Biol 790 150-166 (2013)
  31. Enveloped virus-like particles as vaccines against pathogenic arboviruses. Pijlman GP. Biotechnol J 10 659-670 (2015)
  32. Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines. Salazar-González JA, Angulo C, Rosales-Mendoza S. Vaccine 33 3650-3658 (2015)
  33. Nonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model). Broeckel R, Haese N, Messaoudi I, Streblow DN. Pathogens 4 662-681 (2015)
  34. Virus entry: old viruses, new receptors. Backovic M, Rey FA. Curr Opin Virol 2 4-13 (2012)
  35. Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections. Sautto G, Mancini N, Gorini G, Clementi M, Burioni R. Biomed Res Int 2013 838491 (2013)
  36. Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic. Graham BS, Sullivan NJ. Nat. Immunol. 19 20-28 (2018)
  37. Revisiting an old friend: new findings in alphavirus structure and assembly. Button JM, Qazi SA, Wang JC, Mukhopadhyay S. Curr Opin Virol 45 25-33 (2020)
  38. Structure and working of viral fusion machinery. Albertini A, Bressanelli S, Lepault J, Gaudin Y. Curr Top Membr 68 49-80 (2011)
  39. The Bridges and Blockades to Evolutionary Convergence on the Road to Predicting Chikungunya Virus Evolution. Vignuzzi M, Higgs S. Annu Rev Virol 4 181-200 (2017)
  40. Alphavirus Nucleocapsid Packaging and Assembly. Mendes A, Kuhn RJ. Viruses 10 (2018)
  41. Chikungunya Virus Vaccines: Platforms, Progress, and Challenges. DeFilippis VR. Curr Top Microbiol Immunol 435 81-106 (2022)
  42. Chikungunya virus (CHIKV) inhibitors from natural sources: a medicinal chemistry perspective. Bhakat S, Soliman ME. J Nat Med 69 451-462 (2015)
  43. Current Strategies for Inhibition of Chikungunya Infection. Subudhi BB, Chattopadhyay S, Mishra P, Kumar A. Viruses 10 (2018)
  44. Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections. Keeler SP, Fox JM. Viruses 13 1037 (2021)
  45. Structures of viral membrane proteins by high-resolution cryoEM. Zhou ZH. Curr Opin Virol 5 111-119 (2014)
  46. The Alphavirus Exit Pathway: What We Know and What We Wish We Knew. Brown RS, Wan JJ, Kielian M. Viruses 10 (2018)
  47. Chaperone fusion proteins aid entropy-driven maturation of class II viral fusion proteins. Ge P, Zhou ZH. Trends Microbiol. 22 100-106 (2014)
  48. Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19? Mahmoud DB, Shitu Z, Mostafa A. J Genet Eng Biotechnol 18 35 (2020)
  49. Evolutionary ecology of virus emergence. Dennehy JJ. Ann. N. Y. Acad. Sci. 1389 124-146 (2017)
  50. Genomes to hits in silico - a country path today, a highway tomorrow: a case study of chikungunya. Soni A, Pandey KM, Ray P, Jayaram B. Curr. Pharm. Des. 19 4687-4700 (2013)
  51. Recent Advances in Bunyavirus Glycoprotein Research: Precursor Processing, Receptor Binding and Structure. Hulswit RJG, Paesen GC, Bowden TA, Shi X. Viruses 13 353 (2021)
  52. Antivirals against the Chikungunya Virus. Battisti V, Urban E, Langer T. Viruses 13 1307 (2021)
  53. Chikungunya: A rheumatologist's perspective. Sharma SK, Jain S. Int J Rheum Dis 21 584-601 (2018)
  54. Current Efforts in the Development of Vaccines for the Prevention of Zika and Chikungunya Virus Infections. Schrauf S, Tschismarov R, Tauber E, Ramsauer K. Front Immunol 11 592 (2020)
  55. Entry of Phenuiviruses into Mammalian Host Cells. Koch J, Xin Q, Tischler ND, Lozach PY. Viruses 13 299 (2021)
  56. The Interplay of Viral and Host Factors in Chikungunya Virus Infection: Targets for Antiviral Strategies. Wong KZ, Chu JJH. Viruses 10 (2018)
  57. Viral arthritides. Outhred AC, Kok J, Dwyer DE. Expert Rev Anti Infect Ther 9 545-554 (2011)
  58. Alphavirus Virulence Determinants. Rangel MV, Stapleford KA. Pathogens 10 981 (2021)
  59. Overview on Chikungunya Virus Infection: From Epidemiology to State-of-the-Art Experimental Models. Constant LEC, Rajsfus BF, Carneiro PH, Sisnande T, Mohana-Borges R, Allonso D. Front Microbiol 12 744164 (2021)
  60. Recent progress on chikungunya virus research. An W, Ge N, Cao Y, Sun J, Jin X. Virol Sin 32 441-453 (2017)
  61. Small Molecule Inhibitors Targeting Chikungunya Virus. Haese N, Powers J, Streblow DN. Curr Top Microbiol Immunol 435 107-139 (2022)
  62. Sulfotransferase and Heparanase: Remodeling Engines in Promoting Virus Infection and Disease Development. Kaltenbach DD, Jaishankar D, Hao M, Beer JC, Volin MV, Desai UR, Tiwari V. Front Pharmacol 9 1315 (2018)
  63. A Frame-by-Frame Glance at Membrane Fusion Mechanisms: From Viral Infections to Fertilization. Azimi FC, Dean TT, Minari K, Basso LGM, Vance TDR, Serrão VHB. Biomolecules 13 1130 (2023)
  64. A Review: The Antiviral Activity of Cyclic Peptides. Chia LY, Kumar PV, Maki MAA, Ravichandran G, Thilagar S. Int J Pept Res Ther 29 7 (2023)
  65. A molecular understanding of alphavirus entry and antibody protection. Kim AS, Diamond MS. Nat Rev Microbiol (2022)
  66. A review on structural genomics approach applied for drug discovery against three vector-borne viral diseases: Dengue, Chikungunya and Zika. Sundar S, Piramanayagam S, Natarajan J. Virus Genes 58 151-171 (2022)
  67. Alphavirus Replication: The Role of Cardiac Glycosides and Ion Concentration in Host Cells. Souza-Souza KFC, Gonçalves-de-Albuquerque CF, Cirne-Santos C, Paixão ICNP, Burth P. Biomed Res Int 2020 2813253 (2020)
  68. Alphavirus-Induced Membrane Rearrangements during Replication, Assembly, and Budding. Elmasri Z, Nasal BL, Jose J. Pathogens 10 984 (2021)
  69. An overview of the role of Niemann-pick C1 (NPC1) in viral infections and inhibition of viral infections through NPC1 inhibitor. Ahmad I, Fatemi SN, Ghaheri M, Rezvani A, Khezri DA, Natami M, Yasamineh S, Gholizadeh O, Bahmanyar Z. Cell Commun Signal 21 352 (2023)
  70. Antiviral Functions of Monoclonal Antibodies against Chikungunya Virus. Jin J, Simmons G. Viruses 11 (2019)
  71. Cellular Attachment and Entry Factors for Chikungunya Virus. Schnierle BS. Viruses 11 (2019)
  72. Cellular and Molecular Immune Response to Chikungunya Virus Infection. Tanabe ISB, Tanabe ELL, Santos EC, Martins WV, Araújo IMTC, Cavalcante MCA, Lima ARV, Câmara NOS, Anderson L, Yunusov D, Bassi ÊJ. Front Cell Infect Microbiol 8 345 (2018)
  73. Chikungunya Vaccine Candidates: Current Landscape and Future Prospects. Schmidt C, Schnierle BS. Drug Des Devel Ther 16 3663-3673 (2022)
  74. Chikungunya Virus Diagnosis: A Review of Current Antigen Detection Methods. Simo FBN, Burt FJ, Makoah NA. Trop Med Infect Dis 8 365 (2023)
  75. Chikungunya Virus: An Emergent Arbovirus to the South American Continent and a Continuous Threat to the World. Cunha MS, Costa PAG, Correa IA, de Souza MRM, Calil PT, da Silva GPD, Costa SM, Fonseca VWP, da Costa LJ. Front Microbiol 11 1297 (2020)
  76. Chikungunya and Zika Viruses: Co-Circulation and the Interplay between Viral Proteins and Host Factors. Wichit S, Gumpangseth N, Hamel R, Yainoy S, Arikit S, Punsawad C, Missé D. Pathogens 10 448 (2021)
  77. Chikungunya fever. Bartholomeeusen K, Daniel M, LaBeaud DA, Gasque P, Peeling RW, Stephenson KE, Ng LFP, Ariën KK. Nat Rev Dis Primers 9 17 (2023)
  78. Chikungunya in Infants and Children: Is Pathogenesis Increasing? Barr KL, Vaidhyanathan V. Viruses 11 (2019)
  79. Entry receptors - the gateway to alphavirus infection. Zimmerman O, Holmes AC, Kafai NM, Adams LJ, Diamond MS. J Clin Invest 133 e165307 (2023)
  80. Evolution and immunopathology of chikungunya virus informs therapeutic development. Henderson Sousa F, Ghaisani Komarudin A, Findlay-Greene F, Bowolaksono A, Sasmono RT, Stevens C, Barlow PG. Dis Model Mech 16 dmm049804 (2023)
  81. Fusexins, HAP2/GCS1 and Evolution of Gamete Fusion. Brukman NG, Li X, Podbilewicz B. Front Cell Dev Biol 9 824024 (2021)
  82. Genome-Wide Approaches to Unravel the Host Factors Involved in Chikungunya Virus Replication. Tanaka A, Suzuki Y. Front Microbiol 13 866271 (2022)
  83. Human Genetic Host Factors and Its Role in the Pathogenesis of Chikungunya Virus Infection. Rueda JC, Arcos-Burgos M, Santos AM, Martin-Arsanios D, Villota-Erazo C, Reyes V, Bernal-Macías S, Peláez-Ballestas I, Cardiel MH, Londono J. Front Med (Lausanne) 9 654395 (2022)
  84. Influence of host genetic polymorphisms involved in immune response and their role in the development of Chikungunya disease: a review. Gotay WJP, Rodrigues RO, Yaochite JNU. Braz J Med Biol Res 56 e12557 (2023)
  85. Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape. Torres-Ruesta A, Chee RS, Ng LFP. Microorganisms 9 899 (2021)
  86. Legume Lectins with Different Specificities as Potential Glycan Probes for Pathogenic Enveloped Viruses. Barre A, Van Damme EJM, Klonjkowski B, Simplicien M, Sudor J, Benoist H, Rougé P. Cells 11 339 (2022)
  87. Luciferase Immunosorbent Assay Based on Multiple E Antigens for the Detection of Chikungunya Virus-Specific IgG Antibodies. Li X, Wan X, Liu J, Wang H, Li A, Ke C, Tang S, Zhao W, Cai S, Wan C. Microbiol Spectr 10 e0149621 (2022)
  88. Norovirus Attachment and Entry. Graziano VR, Wei J, Wilen CB. Viruses 11 (2019)
  89. Small-Molecule Inhibition of Viral Fusion Glycoproteins. Liu HY, Yang PL. Annu Rev Virol 8 459-489 (2021)
  90. The Proteolytic Regulation of Virus Cell Entry by Furin and Other Proprotein Convertases. Izaguirre G. Viruses 11 (2019)
  91. The Structural Biology of Eastern Equine Encephalitis Virus, an Emerging Viral Threat. Hasan SS, Dey D, Singh S, Martin M. Pathogens 10 973 (2021)
  92. The Viral Class II Membrane Fusion Machinery: Divergent Evolution from an Ancestral Heterodimer. Guardado-Calvo P, Rey FA. Viruses 13 2368 (2021)
  93. The origin and continuing adaptive evolution of chikungunya virus. Hakim MS, Annisa L, Gazali FM, Aman AT. Arch Virol 167 2443-2455 (2022)
  94. Vaccine development for mosquito-borne viral diseases. Huang Z, Zhang Y, Li H, Zhu J, Song W, Chen K, Zhang Y, Lou Y. Front Immunol 14 1161149 (2023)

Articles citing this publication (275)

  1. Hepatitis C virus E2 envelope glycoprotein core structure. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, Dai X, Stanfield RL, Burton DR, Ward AB, Wilson IA, Law M. Science 342 1090-1094 (2013)
  2. High level of vector competence of Aedes aegypti and Aedes albopictus from ten American countries as a crucial factor in the spread of Chikungunya virus. Vega-Rúa A, Zouache K, Girod R, Failloux AB, Lourenço-de-Oliveira R. J. Virol. 88 6294-6306 (2014)
  3. Sequential adaptive mutations enhance efficient vector switching by Chikungunya virus and its epidemic emergence. Tsetsarkin KA, Weaver SC. PLoS Pathog. 7 e1002412 (2011)
  4. Multi-peaked adaptive landscape for chikungunya virus evolution predicts continued fitness optimization in Aedes albopictus mosquitoes. Tsetsarkin KA, Chen R, Yun R, Rossi SL, Plante KS, Guerbois M, Forrester N, Perng GC, Sreekumar E, Leal G, Huang J, Mukhopadhyay S, Weaver SC. Nat Commun 5 4084 (2014)
  5. 4.4 Å cryo-EM structure of an enveloped alphavirus Venezuelan equine encephalitis virus. Zhang R, Hryc CF, Cong Y, Liu X, Jakana J, Gorchakov R, Baker ML, Weaver SC, Chiu W. EMBO J. 30 3854-3863 (2011)
  6. Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Cockburn JJ, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, Kikuti CM, Coffey LL, Arenzana Seisdedos F, Bedouelle H, Rey FA. Structure 20 303-314 (2012)
  7. Structural characterization of an early fusion intermediate of influenza virus hemagglutinin. Xu R, Wilson IA. J. Virol. 85 5172-5182 (2011)
  8. Crystal structure of glycoprotein C from Rift Valley fever virus. Dessau M, Modis Y. Proc. Natl. Acad. Sci. U.S.A. 110 1696-1701 (2013)
  9. Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. Gorchakov R, Wang E, Leal G, Forrester NL, Plante K, Rossi SL, Partidos CD, Adams AP, Seymour RL, Weger J, Borland EM, Sherman MB, Powers AM, Osorio JE, Weaver SC. J. Virol. 86 6084-6096 (2012)
  10. Natural resistance-associated macrophage protein is a cellular receptor for sindbis virus in both insect and mammalian hosts. Rose PP, Hanna SL, Spiridigliozzi A, Wannissorn N, Beiting DP, Ross SR, Hardy RW, Bambina SA, Heise MT, Cherry S. Cell Host Microbe 10 97-104 (2011)
  11. Mapping of Chikungunya virus interactions with host proteins identified nsP2 as a highly connected viral component. Bouraï M, Lucas-Hourani M, Gad HH, Drosten C, Jacob Y, Tafforeau L, Cassonnet P, Jones LM, Judith D, Couderc T, Lecuit M, André P, Kümmerer BM, Lotteau V, Desprès P, Tangy F, Vidalain PO. J. Virol. 86 3121-3134 (2012)
  12. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. Lee CY, Kam YW, Fric J, Malleret B, Koh EG, Prakash C, Huang W, Lee WW, Lin C, Lin RT, Renia L, Wang CI, Ng LF, Warter L. PLoS Pathog. 7 e1002390 (2011)
  13. Identification of prohibitin as a Chikungunya virus receptor protein. Wintachai P, Wikan N, Kuadkitkan A, Jaimipuk T, Ubol S, Pulmanausahakul R, Auewarakul P, Kasinrerk W, Weng WY, Panyasrivanit M, Paemanee A, Kittisenachai S, Roytrakul S, Smith DR. J. Med. Virol. 84 1757-1770 (2012)
  14. In vitro antiviral activity of arbidol against Chikungunya virus and characteristics of a selected resistant mutant. Delogu I, Pastorino B, Baronti C, Nougairède A, Bonnet E, de Lamballerie X. Antiviral Res. 90 99-107 (2011)
  15. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection. García-Arriaza J, Cepeda V, Hallengärd D, Sorzano CÓ, Kümmerer BM, Liljeström P, Esteban M. J. Virol. 88 3527-3547 (2014)
  16. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Brandler S, Ruffié C, Combredet C, Brault JB, Najburg V, Prevost MC, Habel A, Tauber E, Desprès P, Tangy F. Vaccine 31 3718-3725 (2013)
  17. SbsB structure and lattice reconstruction unveil Ca2+ triggered S-layer assembly. Baranova E, Fronzes R, Garcia-Pino A, Van Gerven N, Papapostolou D, Péhau-Arnaudet G, Pardon E, Steyaert J, Howorka S, Remaut H. Nature 487 119-122 (2012)
  18. Functional and evolutionary insight from the crystal structure of rubella virus protein E1. DuBois RM, Vaney MC, Tortorici MA, Kurdi RA, Barba-Spaeth G, Krey T, Rey FA. Nature 493 552-556 (2013)
  19. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. Hallengärd D, Kakoulidou M, Lulla A, Kümmerer BM, Johansson DX, Mutso M, Lulla V, Fazakerley JK, Roques P, Le Grand R, Merits A, Liljeström P. J. Virol. 88 2858-2866 (2014)
  20. BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1). Jones PH, Maric M, Madison MN, Maury W, Roller RJ, Okeoma CM. Virology 438 37-49 (2013)
  21. Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization. Sun S, Xiang Y, Akahata W, Holdaway H, Pal P, Zhang X, Diamond MS, Nabel GJ, Rossmann MG. Elife 2 e00435 (2013)
  22. Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress. Fox JM, Long F, Edeling MA, Lin H, van Duijl-Richter MKS, Fong RH, Kahle KM, Smit JM, Jin J, Simmons G, Doranz BJ, Crowe JE, Fremont DH, Rossmann MG, Diamond MS. Cell 163 1095-1107 (2015)
  23. A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease. Selvarajah S, Sexton NR, Kahle KM, Fong RH, Mattia KA, Gardner J, Lu K, Liss NM, Salvador B, Tucker DF, Barnes T, Mabila M, Zhou X, Rossini G, Rucker JB, Sanders DA, Suhrbier A, Sambri V, Michault A, Muench MO, Doranz BJ, Simmons G. PLoS Negl Trop Dis 7 e2423 (2013)
  24. Differential unfolded protein response during Chikungunya and Sindbis virus infection: CHIKV nsP4 suppresses eIF2α phosphorylation. Rathore AP, Ng ML, Vasudevan SG. Virol. J. 10 36 (2013)
  25. Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells. Metz SW, Geertsema C, Martina BE, Andrade P, Heldens JG, van Oers MM, Goldbach RW, Vlak JM, Pijlman GP. Virol. J. 8 353 (2011)
  26. Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus. Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS, Crowe JE. Cell Host Microbe 18 86-95 (2015)
  27. Chikungunya virus transmission potential by local Aedes mosquitoes in the Americas and Europe. Vega-Rúa A, Lourenço-de-Oliveira R, Mousson L, Vazeille M, Fuchs S, Yébakima A, Gustave J, Girod R, Dusfour I, Leparc-Goffart I, Vanlandingham DL, Huang YJ, Lounibos LP, Mohamed Ali S, Nougairede A, de Lamballerie X, Failloux AB. PLoS Negl Trop Dis 9 e0003780 (2015)
  28. Emergence and transmission of arbovirus evolutionary intermediates with epidemic potential. Stapleford KA, Coffey LL, Lay S, Bordería AV, Duong V, Isakov O, Rozen-Gagnon K, Arias-Goeta C, Blanc H, Beaucourt S, Haliloğlu T, Schmitt C, Bonne I, Ben-Tal N, Shomron N, Failloux AB, Buchy P, Vignuzzi M. Cell Host Microbe 15 706-716 (2014)
  29. Functional characterization of the alphavirus TF protein. Snyder JE, Kulcsar KA, Schultz KL, Riley CP, Neary JT, Marr S, Jose J, Griffin DE, Kuhn RJ. J. Virol. 87 8511-8523 (2013)
  30. Genotypic and phenotypic characterization of Chikungunya virus of different genotypes from Malaysia. Sam IC, Loong SK, Michael JC, Chua CL, Wan Sulaiman WY, Vythilingam I, Chan SY, Chiam CW, Yeong YS, AbuBakar S, Chan YF. PLoS ONE 7 e50476 (2012)
  31. Exposure of epitope residues on the outer face of the chikungunya virus envelope trimer determines antibody neutralizing efficacy. Fong RH, Banik SS, Mattia K, Barnes T, Tucker D, Liss N, Lu K, Selvarajah S, Srinivasan S, Mabila M, Miller A, Muench MO, Michault A, Rucker JB, Paes C, Simmons G, Kahle KM, Doranz BJ. J. Virol. 88 14364-14379 (2014)
  32. Acidic pH-Induced Conformations and LAMP1 Binding of the Lassa Virus Glycoprotein Spike. Li S, Sun Z, Pryce R, Parsy ML, Fehling SK, Schlie K, Siebert CA, Garten W, Bowden TA, Strecker T, Huiskonen JT. PLoS Pathog. 12 e1005418 (2016)
  33. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Chu H, Das SC, Fuchs JF, Suresh M, Weaver SC, Stinchcomb DT, Partidos CD, Osorio JE. Vaccine 31 3353-3360 (2013)
  34. Molecular links between the E2 envelope glycoprotein and nucleocapsid core in Sindbis virus. Tang J, Jose J, Chipman P, Zhang W, Kuhn RJ, Baker TS. J. Mol. Biol. 414 442-459 (2011)
  35. Prime-boost immunization strategies against Chikungunya virus. Hallengärd D, Lum FM, Kümmerer BM, Lulla A, Lulla V, García-Arriaza J, Fazakerley JK, Roques P, Le Grand R, Merits A, Ng LF, Esteban M, Liljeström P. J. Virol. 88 13333-13343 (2014)
  36. Mechanisms of Virus Membrane Fusion Proteins. Kielian M. Annu Rev Virol 1 171-189 (2014)
  37. Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo. Rathore AP, Haystead T, Das PK, Merits A, Ng ML, Vasudevan SG. Antiviral Res. 103 7-16 (2014)
  38. Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2. Boo I, teWierik K, Douam F, Lavillette D, Poumbourios P, Drummer HE. Biochem. J. 443 85-94 (2012)
  39. The green tea catechin, epigallocatechin gallate inhibits chikungunya virus infection. Weber C, Sliva K, von Rhein C, Kümmerer BM, Schnierle BS. Antiviral Res. 113 1-3 (2015)
  40. Chikungunya viruses that escape monoclonal antibody therapy are clinically attenuated, stable, and not purified in mosquitoes. Pal P, Fox JM, Hawman DW, Huang YJ, Messaoudi I, Kreklywich C, Denton M, Legasse AW, Smith PP, Johnson S, Axthelm MK, Vanlandingham DL, Streblow DN, Higgs S, Morrison TE, Diamond MS. J. Virol. 88 8213-8226 (2014)
  41. A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design. Akahata W, Nabel GJ. J. Virol. 86 8879-8883 (2012)
  42. Fine mapping of murine antibody responses to immunization with a novel soluble form of hepatitis C virus envelope glycoprotein complex. Ruwona TB, Giang E, Nieusma T, Law M. J. Virol. 88 10459-10471 (2014)
  43. Heat shock protein 90 positively regulates Chikungunya virus replication by stabilizing viral non-structural protein nsP2 during infection. Das I, Basantray I, Mamidi P, Nayak TK, B M P, Chattopadhyay S, Chattopadhyay S. PLoS ONE 9 e100531 (2014)
  44. Interactions of the cytoplasmic domain of Sindbis virus E2 with nucleocapsid cores promote alphavirus budding. Jose J, Przybyla L, Edwards TJ, Perera R, Burgner JW, Kuhn RJ. J. Virol. 86 2585-2599 (2012)
  45. The alphavirus E3 glycoprotein functions in a clade-specific manner. Snyder AJ, Mukhopadhyay S. J. Virol. 86 13609-13620 (2012)
  46. Genetic diversity of Chikungunya virus, India 2006-2010: evolutionary dynamics and serotype analyses. Sumathy K, Ella KM. J. Med. Virol. 84 462-470 (2012)
  47. Imaging the alphavirus exit pathway. Martinez MG, Snapp EL, Perumal GS, Macaluso FP, Kielian M. J. Virol. 88 6922-6933 (2014)
  48. Residue 82 of the Chikungunya virus E2 attachment protein modulates viral dissemination and arthritis in mice. Ashbrook AW, Burrack KS, Silva LA, Montgomery SA, Heise MT, Morrison TE, Dermody TS. J. Virol. 88 12180-12192 (2014)
  49. Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development. Kam YW, Lee WW, Simarmata D, Le Grand R, Tolou H, Merits A, Roques P, Ng LF. PLoS ONE 9 e95647 (2014)
  50. Ebolavirus entry requires a compact hydrophobic fist at the tip of the fusion loop. Gregory SM, Larsson P, Nelson EA, Kasson PM, White JM, Tamm LK. J. Virol. 88 6636-6649 (2014)
  51. Identical strength of the T cell responses against E2, nsP1 and capsid CHIKV proteins in recovered and chronic patients after the epidemics of 2005-2006 in La Reunion Island. Hoarau JJ, Gay F, Pellé O, Samri A, Jaffar-Bandjee MC, Gasque P, Autran B. PLoS ONE 8 e84695 (2013)
  52. Locking and blocking the viral landscape of an alphavirus with neutralizing antibodies. Porta J, Jose J, Roehrig JT, Blair CD, Kuhn RJ, Rossmann MG. J. Virol. 88 9616-9623 (2014)
  53. The role of E3 in pH protection during alphavirus assembly and exit. Uchime O, Fields W, Kielian M. J. Virol. 87 10255-10262 (2013)
  54. Antiviral activities of niclosamide and nitazoxanide against chikungunya virus entry and transmission. Wang YM, Lu JW, Lin CC, Chin YF, Wu TY, Lin LI, Lai ZZ, Kuo SC, Ho YJ. Antiviral Res. 135 81-90 (2016)
  55. Dynamics of Chikungunya Virus Cell Entry Unraveled by Single-Virus Tracking in Living Cells. Hoornweg TE, van Duijl-Richter MKS, Ayala Nuñez NV, Albulescu IC, van Hemert MJ, Smit JM. J. Virol. 90 4745-4756 (2016)
  56. Neurovirulence comparison of chikungunya virus isolates of the Asian and East/Central/South African genotypes from Malaysia. Wei Chiam C, Fun Chan Y, Chai Ong K, Thong Wong K, Sam IC. J. Gen. Virol. 96 3243-3254 (2015)
  57. An assembly model of rift valley Fever virus. Rusu M, Bonneau R, Holbrook MR, Watowich SJ, Birmanns S, Wriggers W, Freiberg AN. Front Microbiol 3 254 (2012)
  58. Structure of the St. Louis encephalitis virus postfusion envelope trimer. Luca VC, Nelson CA, Fremont DH. J. Virol. 87 818-828 (2013)
  59. The domain I-domain III linker plays an important role in the fusogenic conformational change of the alphavirus membrane fusion protein. Zheng Y, Sánchez-San Martín C, Qin ZL, Kielian M. J. Virol. 85 6334-6342 (2011)
  60. Cell-based analysis of Chikungunya virus E1 protein in membrane fusion. Kuo SC, Chen YJ, Wang YM, Tsui PY, Kuo MD, Wu TY, Lo SJ. J. Biomed. Sci. 19 44 (2012)
  61. Chikungunya virus adaptation to Aedes albopictus mosquitoes does not correlate with acquisition of cholesterol dependence or decreased pH threshold for fusion reaction. Tsetsarkin KA, McGee CE, Higgs S. Virol. J. 8 376 (2011)
  62. Development of a pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection. Kishishita N, Takeda N, Anuegoonpipat A, Anantapreecha S. J. Clin. Microbiol. 51 1389-1395 (2013)
  63. The amino-terminal domain of alphavirus capsid protein is dispensable for viral particle assembly but regulates RNA encapsidation through cooperative functions of its subdomains. Lulla V, Kim DY, Frolova EI, Frolov I. J. Virol. 87 12003-12019 (2013)
  64. The cell biology of Chikungunya virus infection. Tang BL. Cell. Microbiol. 14 1354-1363 (2012)
  65. A small antigenic determinant of the Chikungunya virus E2 protein is sufficient to induce neutralizing antibodies which are partially protective in mice. Weber C, Büchner SM, Schnierle BS. PLoS Negl Trop Dis 9 e0003684 (2015)
  66. Activation of the alphavirus spike protein is suppressed by bound E3. Sjöberg M, Lindqvist B, Garoff H. J. Virol. 85 5644-5650 (2011)
  67. Involvement of ATP synthase β subunit in chikungunya virus entry into insect cells. Fongsaran C, Jirakanwisal K, Kuadkitkan A, Wikan N, Wintachai P, Thepparit C, Ubol S, Phaonakrop N, Roytrakul S, Smith DR. Arch. Virol. 159 3353-3364 (2014)
  68. Kinetic and phenotypic analysis of CD8+ T cell responses after priming with alphavirus replicons and homologous or heterologous booster immunizations. Knudsen ML, Ljungberg K, Kakoulidou M, Kostic L, Hallengärd D, García-Arriaza J, Merits A, Esteban M, Liljeström P. J. Virol. 88 12438-12451 (2014)
  69. Mutating conserved cysteines in the alphavirus e2 glycoprotein causes virus-specific assembly defects. Snyder AJ, Sokoloski KJ, Mukhopadhyay S. J. Virol. 86 3100-3111 (2012)
  70. Ability of the Encephalitic Arbovirus Semliki Forest Virus To Cross the Blood-Brain Barrier Is Determined by the Charge of the E2 Glycoprotein. Ferguson MC, Saul S, Fragkoudis R, Weisheit S, Cox J, Patabendige A, Sherwood K, Watson M, Merits A, Fazakerley JK. J. Virol. 89 7536-7549 (2015)
  71. Characterization of an early-stage fusion intermediate of Sindbis virus using cryoelectron microscopy. Cao S, Zhang W. Proc. Natl. Acad. Sci. U.S.A. 110 13362-13367 (2013)
  72. Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate. Plante KS, Rossi SL, Bergren NA, Seymour RL, Weaver SC. PLoS Negl Trop Dis 9 e0004007 (2015)
  73. Suramin is a potent inhibitor of Chikungunya and Ebola virus cell entry. Henß L, Beck S, Weidner T, Biedenkopf N, Sliva K, Weber C, Becker S, Schnierle BS. Virol. J. 13 149 (2016)
  74. pH-induced stability switching of the bacteriophage HK97 maturation pathway. May ER, Arora K, Brooks CL. J. Am. Chem. Soc. 136 3097-3107 (2014)
  75. A key interaction between the alphavirus envelope proteins responsible for initial dimer dissociation during fusion. Fields W, Kielian M. J. Virol. 87 3774-3781 (2013)
  76. Assessment of flavaglines as potential chikungunya virus entry inhibitors. Wintachai P, Thuaud F, Basmadjian C, Roytrakul S, Ubol S, Désaubry L, Smith DR. Microbiol. Immunol. 59 129-141 (2015)
  77. BST2/tetherin inhibition of alphavirus exit. Ooi YS, Dubé M, Kielian M. Viruses 7 2147-2167 (2015)
  78. Cryo-EM structures elucidate neutralizing mechanisms of anti-chikungunya human monoclonal antibodies with therapeutic activity. Long F, Fong RH, Austin SK, Chen Z, Klose T, Fokine A, Liu Y, Porta J, Sapparapu G, Akahata W, Doranz BJ, Crowe JE, Diamond MS, Rossmann MG. Proc. Natl. Acad. Sci. U.S.A. 112 13898-13903 (2015)
  79. Human mAbs Broadly Protect against Arthritogenic Alphaviruses by Recognizing Conserved Elements of the Mxra8 Receptor-Binding Site. Powell LA, Miller A, Fox JM, Kose N, Klose T, Kim AS, Bombardi R, Tennekoon RN, Dharshan de Silva A, Carnahan RH, Diamond MS, Rossmann MG, Kuhn RJ, Crowe JE. Cell Host Microbe 28 699-711.e7 (2020)
  80. Imipramine Inhibits Chikungunya Virus Replication in Human Skin Fibroblasts through Interference with Intracellular Cholesterol Trafficking. Wichit S, Hamel R, Bernard E, Talignani L, Diop F, Ferraris P, Liegeois F, Ekchariyawat P, Luplertlop N, Surasombatpattana P, Thomas F, Merits A, Choumet V, Roques P, Yssel H, Briant L, Missé D. Sci Rep 7 3145 (2017)
  81. Molecular investigations of chikungunya virus during outbreaks in Orissa, Eastern India in 2010. Das B, Sahu A, Das M, Patra A, Dwibedi B, Kar SK, Hazra RK. Infect. Genet. Evol. 12 1094-1101 (2012)
  82. Structural basis of Chikungunya virus inhibition by monoclonal antibodies. Zhou QF, Fox JM, Earnest JT, Ng TS, Kim AS, Fibriansah G, Kostyuchenko VA, Shi J, Shu B, Diamond MS, Lok SM. Proc Natl Acad Sci U S A 117 27637-27645 (2020)
  83. Suramin Inhibits Chikungunya Virus Entry and Transmission. Ho YJ, Wang YM, Lu JW, Wu TY, Lin LI, Kuo SC, Lin CC. PLoS ONE 10 e0133511 (2015)
  84. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus. Roques P, Ljungberg K, Kümmerer BM, Gosse L, Dereuddre-Bosquet N, Tchitchek N, Hallengärd D, García-Arriaza J, Meinke A, Esteban M, Merits A, Le Grand R, Liljeström P. JCI Insight 2 e83527 (2017)
  85. Fluorescent Protein-Tagged Sindbis Virus E2 Glycoprotein Allows Single Particle Analysis of Virus Budding from Live Cells. Jose J, Tang J, Taylor AB, Baker TS, Kuhn RJ. Viruses 7 6182-6199 (2015)
  86. Loss of Glycosaminoglycan Receptor Binding after Mosquito Cell Passage Reduces Chikungunya Virus Infectivity. Acharya D, Paul AM, Anderson JF, Huang F, Bai F. PLoS Negl Trop Dis 9 e0004139 (2015)
  87. Mxra8 is a receptor for multiple arthritogenic alphaviruses. Zhang R, Kim AS, Fox JM, Nair S, Basore K, Klimstra WB, Rimkunas R, Fong RH, Lin H, Poddar S, Crowe JE, Doranz BJ, Fremont DH, Diamond MS. Nature 557 570-574 (2018)
  88. Re-emergence of Chikungunya virus infection in Eastern India. Sengupta S, Mukherjee S, Haldar SK, Bhattacharya N, Tripathi A. Braz J Microbiol 51 177-182 (2020)
  89. Characterisation of mouse monoclonal antibodies targeting linear epitopes on Chikungunya virus E2 glycoprotein. Chua CL, Chan YF, Sam IC. J. Virol. Methods 195 126-133 (2014)
  90. Correlation of phylogenetic clade diversification and in vitro infectivity differences among Cosmopolitan genotype strains of Chikungunya virus. Abraham R, Manakkadan A, Mudaliar P, Joseph I, Sivakumar KC, Nair RR, Sreekumar E. Infect. Genet. Evol. 37 174-184 (2016)
  91. Curcumin and Boswellia serrata gum resin extract inhibit chikungunya and vesicular stomatitis virus infections in vitro. von Rhein C, Weidner T, Henß L, Martin J, Weber C, Sliva K, Schnierle BS. Antiviral Res. 125 51-57 (2016)
  92. Genetic characterization of E2 region of Chikungunya virus circulating in Odisha, Eastern India from 2010 to 2011. Sahu A, Das B, Das M, Patra A, Biswal S, Kar SK, Hazra RK. Infect. Genet. Evol. 18 113-124 (2013)
  93. Molecular determinants of mouse neurovirulence and mosquito infection for Western equine encephalitis virus. Mossel EC, Ledermann JP, Phillips AT, Borland EM, Powers AM, Olson KE. PLoS ONE 8 e60427 (2013)
  94. A neutralization assay for chikungunya virus infections in a multiplex format. Weber C, König R, Niedrig M, Emmerich P, Schnierle BS. J. Virol. Methods 201 7-12 (2014)
  95. Chikungunya virus fusion properties elucidated by single-particle and bulk approaches. van Duijl-Richter MKS, Blijleven JS, van Oijen AM, Smit JM. J. Gen. Virol. 96 2122-2132 (2015)
  96. Computational Approach Towards Exploring Potential Anti-Chikungunya Activity of Selected Flavonoids. Seyedi SS, Shukri M, Hassandarvish P, Oo A, Shankar EM, Abubakar S, Zandi K. Sci Rep 6 24027 (2016)
  97. Cryo-EM Structure of Chikungunya Virus in Complex with the Mxra8 Receptor. Basore K, Kim AS, Nelson CA, Zhang R, Smith BK, Uranga C, Vang L, Cheng M, Gross ML, Smith J, Diamond MS, Fremont DH. Cell 177 1725-1737.e16 (2019)
  98. Case Reports Fatal Rhabdomyolysis in a COVID-19 Patient on Rosuvastatin. Anklesaria Z, Frankman J, Gordin J, Zhan J, Liu AK. Cureus 12 e11186 (2020)
  99. Identifying the Role of E2 Domains on Alphavirus Neutralization and Protective Immune Responses. Weger-Lucarelli J, Aliota MT, Kamlangdee A, Osorio JE. PLoS Negl Trop Dis 9 e0004163 (2015)
  100. Residue-level resolution of alphavirus envelope protein interactions in pH-dependent fusion. Zeng X, Mukhopadhyay S, Brooks CL. Proc. Natl. Acad. Sci. U.S.A. 112 2034-2039 (2015)
  101. Structure based design towards the identification of novel binding sites and inhibitors for the chikungunya virus envelope proteins. Rashad AA, Keller PA. J. Mol. Graph. Model. 44 241-252 (2013)
  102. The interaction of alphavirus E1 protein with exogenous domain III defines stages in virus-membrane fusion. Roman-Sosa G, Kielian M. J. Virol. 85 12271-12279 (2011)
  103. Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques. Broeckel R, Fox JM, Haese N, Kreklywich CN, Sukulpovi-Petty S, Legasse A, Smith PP, Denton M, Corvey C, Krishnan S, Colgin LMA, Ducore RM, Lewis AD, Axthelm MK, Mandron M, Cortez P, Rothblatt J, Rao E, Focken I, Carter K, Sapparapau G, Crowe JE, Diamond MS, Streblow DN. PLoS Negl Trop Dis 11 e0005637 (2017)
  104. Antigenic Variation of East/Central/South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera. Chua CL, Sam IC, Merits A, Chan YF. PLoS Negl Trop Dis 10 e0004960 (2016)
  105. Chikungunya emergency in China: microevolution and genetic analysis for a local outbreak. Lu X, Li X, Mo Z, Jin F, Wang B, Huang J, Huang J, Zhao H, Shi L. Virus Genes 48 15-22 (2014)
  106. Chikungunya virus was isolated in Thailand, 2010. Sasayama M, Benjathummarak S, Kawashita N, Rukmanee P, Sangmukdanun S, Masrinoul P, Pitaksajjakul P, Puiprom O, Wuthisen P, Kurosu T, Chaichana P, Maneekan P, Ikuta K, Ramasoota P, Okabayashi T, Singhasivanon P, Luplertlop N. Virus Genes 49 485-489 (2014)
  107. Shielding and activation of a viral membrane fusion protein. Halldorsson S, Li S, Li M, Harlos K, Bowden TA, Huiskonen JT. Nat Commun 9 349 (2018)
  108. Structural Studies of Chikungunya Virus-Like Particles Complexed with Human Antibodies: Neutralization and Cell-to-Cell Transmission. Porta J, Mangala Prasad V, Wang CI, Akahata W, Ng LF, Rossmann MG. J. Virol. 90 1169-1177 (2016)
  109. A tyrosine-to-histidine switch at position 18 of the Ross River virus E2 glycoprotein is a determinant of virus fitness in disparate hosts. Jupille HJ, Medina-Rivera M, Hawman DW, Oko L, Morrison TE. J. Virol. 87 5970-5984 (2013)
  110. An Alphavirus E2 Membrane-Proximal Domain Promotes Envelope Protein Lateral Interactions and Virus Budding. Byrd EA, Kielian M. MBio 8 (2017)
  111. Cell-based analysis of Chikungunya virus membrane fusion using baculovirus-expression vectors. Kuo SC, Chen YJ, Wang YM, Kuo MD, Jinn TR, Chen WS, Chang YC, Tung KL, Wu TY, Lo SJ. J. Virol. Methods 175 206-215 (2011)
  112. Cross-inhibition of chikungunya virus fusion and infection by alphavirus E1 domain III proteins. Sánchez-San Martín C, Nanda S, Zheng Y, Fields W, Kielian M. J. Virol. 87 7680-7687 (2013)
  113. Directed evolution of a virus exclusively utilizing human epidermal growth factor receptor as the entry receptor. Dai HS, Liu Z, Jiang W, Kuhn RJ. J. Virol. 87 11231-11243 (2013)
  114. Dissecting the Role of E2 Protein Domains in Alphavirus Pathogenicity. Weger-Lucarelli J, Aliota MT, Wlodarchak N, Kamlangdee A, Swanson R, Osorio JE. J. Virol. 90 2418-2433 (2015)
  115. Genetic Characterization of Northwestern Colombian Chikungunya Virus Strains from the 2014-2015 Epidemic. Rodas JD, Kautz T, Camacho E, Paternina L, Guzmán H, Díaz FJ, Blanco P, Tesh R, Weaver SC. Am. J. Trop. Med. Hyg. 95 639-646 (2016)
  116. Genome-Wide Screening Uncovers the Significance of N-Sulfation of Heparan Sulfate as a Host Cell Factor for Chikungunya Virus Infection. Tanaka A, Tumkosit U, Nakamura S, Motooka D, Kishishita N, Priengprom T, Sa-Ngasang A, Kinoshita T, Takeda N, Maeda Y. J. Virol. 91 (2017)
  117. Identification of Functional Determinants in the Chikungunya Virus E2 Protein. Weber C, Berberich E, von Rhein C, Henß L, Hildt E, Schnierle BS. PLoS Negl Trop Dis 11 e0005318 (2017)
  118. Identification of chikungunya virus nsP2 protease inhibitors using structure-base approaches. Nguyen PT, Yu H, Keller PA. J. Mol. Graph. Model. 57 1-8 (2015)
  119. Identification of structural motifs in the E2 glycoprotein of Chikungunya involved in virus-host interaction. Asnet Mary J, Paramasivan R, Tyagi BK, Surender M, Shenbagarathai R. J. Biomol. Struct. Dyn. 31 1077-1085 (2013)
  120. Independent Emergence of the Cosmopolitan Asian Chikungunya Virus, Philippines 2012. Tan KK, Sy AK, Tandoc AO, Khoo JJ, Sulaiman S, Chang LY, AbuBakar S. Sci Rep 5 12279 (2015)
  121. A glycerophospholipid-specific pocket in the RVFV class II fusion protein drives target membrane insertion. Guardado-Calvo P, Atkovska K, Jeffers SA, Grau N, Backovic M, Pérez-Vargas J, de Boer SM, Tortorici MA, Pehau-Arnaudet G, Lepault J, England P, Rottier PJ, Bosch BJ, Hub JS, Rey FA. Science 358 663-667 (2017)
  122. Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria. Francica JR, Shi W, Chuang GY, Chen SJ, Da Silva Pereira L, Farney SK, Flynn BJ, Ou L, Stephens T, Tsybovsky Y, Wang LT, Anderson A, Beck Z, Dillon M, Idris AH, Hurlburt N, Liu T, Zhang B, Alving CR, Matyas GR, Pancera M, Mascola JR, Kwong PD, Seder RA. Vaccines (Basel) 9 272 (2021)
  123. Development and application of a reversed-phase high-performance liquid chromatographic method for quantitation and characterization of a Chikungunya virus-like particle vaccine. Shytuhina A, Pristatsky P, He J, Casimiro DR, Schwartz RM, Hoang VM, Ha S. J Chromatogr A 1364 192-197 (2014)
  124. Discovery of archaeal fusexins homologous to eukaryotic HAP2/GCS1 gamete fusion proteins. Moi D, Nishio S, Li X, Valansi C, Langleib M, Brukman NG, Flyak K, Dessimoz C, de Sanctis D, Tunyasuvunakool K, Jumper J, Graña M, Romero H, Aguilar PS, Jovine L, Podbilewicz B. Nat Commun 13 3880 (2022)
  125. Discovery of in silico hits targeting the nsP3 macro domain of chikungunya virus. Nguyen PT, Yu H, Keller PA. J Mol Model 20 2216 (2014)
  126. Host-pathogen interactome analysis of Chikungunya virus envelope proteins E1 and E2. Dudha N, Rana J, Rajasekharan S, Gabrani R, Gupta A, Chaudhary VK, Gupta S. Virus Genes 50 200-209 (2015)
  127. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Fels JM, Maurer DP, Herbert AS, Wirchnianski AS, Vergnolle O, Cross RW, Abelson DM, Moyer CL, Mishra AK, Aguilan JT, Kuehne AI, Pauli NT, Bakken RR, Nyakatura EK, Hellert J, Quevedo G, Lobel L, Balinandi S, Lutwama JJ, Zeitlin L, Geisbert TW, Rey FA, Sidoli S, McLellan JS, Lai JR, Bornholdt ZA, Dye JM, Walker LM, Chandran K. Cell 184 3486-3501.e21 (2021)
  128. Structure-function analysis of hepatitis C virus envelope glycoproteins E1 and E2. Nayak A, Pattabiraman N, Fadra N, Goldman R, Kosakovsky Pond SL, Mazumder R. J. Biomol. Struct. Dyn. 33 1682-1694 (2015)
  129. The Postfusion Structure of the Heartland Virus Gc Glycoprotein Supports Taxonomic Separation of the Bunyaviral Families Phenuiviridae and Hantaviridae. Zhu Y, Wu Y, Chai Y, Qi J, Peng R, Feng WH, Gao GF. J. Virol. 92 (2018)
  130. A naturally occurring substitution in the E2 protein of Salmonid alphavirus subtype 3 changes viral fitness. Karlsen M, Andersen L, Blindheim SH, Rimstad E, Nylund A. Virus Res. 196 79-86 (2015)
  131. A polarized cell model for Chikungunya virus infection: entry and egress of virus occurs at the apical domain of polarized cells. Lim PJ, Chu JJ. PLoS Negl Trop Dis 8 e2661 (2014)
  132. Acidic pH-Induced Conformational Changes in Chikungunya Virus Fusion Protein E1: a Spring-Twisted Region in the Domain I-III Linker Acts as a Hinge Point for Swiveling Motion of Domains. Sahoo B, Gudigamolla NK, Chowdary TK. J Virol 94 e01561-20 (2020)
  133. Both ADP-Ribosyl-Binding and Hydrolase Activities of the Alphavirus nsP3 Macrodomain Affect Neurovirulence in Mice. Abraham R, McPherson RL, Dasovich M, Badiee M, Leung AKL, Griffin DE. mBio 11 (2020)
  134. Broad and long-lasting immune protection against various Chikungunya genotypes demonstrated by participants in a cross-sectional study in a Cambodian rural community. Auerswald H, Boussioux C, In S, Mao S, Ong S, Huy R, Leang R, Chan M, Duong V, Ly S, Tarantola A, Dussart P. Emerg Microbes Infect 7 13 (2018)
  135. Calcium-Dependent Rubella Virus Fusion Occurs in Early Endosomes. Dubé M, Etienne L, Fels M, Kielian M. J. Virol. 90 6303-6313 (2016)
  136. Comparative advantages and limitations of the basic metrology methods applied to the characterization of nanomaterials. Linkov P, Artemyev M, Efimov AE, Nabiev I. Nanoscale 5 8781-8798 (2013)
  137. Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein. Rissanen I, Stass R, Krumm SA, Seow J, Hulswit RJ, Paesen GC, Hepojoki J, Vapalahti O, Lundkvist Å, Reynard O, Volchkov V, Doores KJ, Huiskonen JT, Bowden TA. Elife 9 e58242 (2020)
  138. Novel Insect-Specific Eilat Virus-Based Chimeric Vaccine Candidates Provide Durable, Mono- and Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge. Erasmus JH, Seymour RL, Kaelber JT, Kim DY, Leal G, Sherman MB, Frolov I, Chiu W, Weaver SC, Nasar F, Nasar F. J. Virol. 92 (2018)
  139. Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope. Kim AS, Kafai NM, Winkler ES, Gilliland TC, Cottle EL, Earnest JT, Jethva PN, Kaplonek P, Shah AP, Fong RH, Davidson E, Malonis RJ, Quiroz JA, Williamson LE, Vang L, Mack M, Crowe JE, Doranz BJ, Lai JR, Alter G, Gross ML, Klimstra WB, Fremont DH, Diamond MS. Cell 184 4414-4429.e19 (2021)
  140. Structural studies of Chikungunya virus maturation. Yap ML, Klose T, Urakami A, Hasan SS, Akahata W, Rossmann MG. Proc. Natl. Acad. Sci. U.S.A. 114 13703-13707 (2017)
  141. The missing pieces of the HCV entry puzzle. Ogden SC, Tang H. Future Virol 10 415-428 (2015)
  142. A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis. Lam S, Nyo M, Phuektes P, Yew CW, Tan YJ, Chu JJ. MAbs 7 1178-1194 (2015)
  143. Alphavirus entry: NRAMP leads the way. Stiles KM, Kielian M. Cell Host Microbe 10 92-93 (2011)
  144. An alphavirus temperature-sensitive capsid mutant reveals stages of nucleocapsid assembly. Zheng Y, Kielian M. Virology 484 412-420 (2015)
  145. Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release. Tumkosit U, Siripanyaphinyo U, Takeda N, Tsuji M, Maeda Y, Ruchusatsawat K, Shioda T, Mizushima H, Chetanachan P, Wongjaroen P, Matsuura Y, Tatsumi M, Tanaka A. J Virol 94 e00252-20 (2020)
  146. Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus. Urakami A, Sakurai A, Ishikawa M, Yap ML, Flores-Garcia Y, Haseda Y, Aoshi T, Zavala FP, Rossmann MG, Kuno S, Ueno R, Akahata W. Clin. Vaccine Immunol. 24 (2017)
  147. Genetic characterization of chikungunya viruses isolated during the 2015-2017 outbreaks in different states of India, based on their E1 and E2 genes. Patil J, More A, Patil P, Jadhav S, Newase P, Agarwal M, Amdekar S, Raut CG, Parashar D, Cherian SS. Arch. Virol. 163 3135-3140 (2018)
  148. Monoclonal Antibodies as Prophylactic and Therapeutic Agents Against Chikungunya Virus. Clayton AM. J. Infect. Dis. 214 S506-S509 (2016)
  149. Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes. Fox JM, Roy V, Gunn BM, Huang L, Edeling MA, Mack M, Fremont DH, Doranz BJ, Johnson S, Alter G, Diamond MS. Sci Immunol 4 (2019)
  150. Persistence of multiple genetic lineages within intrahost populations of Ross River virus. Liu WJ, Rourke MF, Holmes EC, Aaskov JG. J. Virol. 85 5674-5678 (2011)
  151. Structural Basis for a Neutralizing Antibody Response Elicited by a Recombinant Hantaan Virus Gn Immunogen. Rissanen I, Krumm SA, Stass R, Whitaker A, Voss JE, Bruce EA, Rothenberger S, Kunz S, Burton DR, Huiskonen JT, Botten JW, Bowden TA, Doores KJ. mBio 12 e0253120 (2021)
  152. The SD1 Subdomain of Venezuelan Equine Encephalitis Virus Capsid Protein Plays a Critical Role in Nucleocapsid and Particle Assembly. Reynaud JM, Lulla V, Kim DY, Frolova EI, Frolov I. J. Virol. 90 2008-2020 (2016)
  153. ADP-ribosyl-binding and hydrolase activities of the alphavirus nsP3 macrodomain are critical for initiation of virus replication. Abraham R, Hauer D, McPherson RL, Utt A, Kirby IT, Cohen MS, Merits A, Leung AKL, Griffin DE. Proc. Natl. Acad. Sci. U.S.A. 115 E10457-E10466 (2018)
  154. Alphavirus capsid proteins self-assemble into core-like particles in insect cells: A promising platform for nanoparticle vaccine development. Hikke MC, Geertsema C, Wu V, Metz SW, van Lent JW, Vlak JM, Pijlman GP. Biotechnol J 11 266-273 (2016)
  155. An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses. Ge N, Sun J, Liu Z, Shu J, Yan H, Kou Z, Wei Y, Jin X. Virol Sin 37 266-276 (2022)
  156. Broad-spectrum monoclonal antibodies against chikungunya virus structural proteins: Promising candidates for antibody-based rapid diagnostic test development. Tuekprakhon A, Puiprom O, Sasaki T, Michiels J, Bartholomeeusen K, Nakayama EE, Meno MK, Phadungsombat J, Huits R, Ariën KK, Luplertlop N, Shioda T, Leaungwutiwong P. PLoS ONE 13 e0208851 (2018)
  157. Complex antigen presentation pathway for an HLA-A*0201-restricted epitope from Chikungunya 6K protein. Lorente E, Barriga A, García-Arriaza J, Lemonnier FA, Esteban M, López D. PLoS Negl Trop Dis 11 e0006036 (2017)
  158. Cryo-EM structure of eastern equine encephalitis virus in complex with heparan sulfate analogues. Chen CL, Hasan SS, Klose T, Sun Y, Buda G, Sun C, Klimstra WB, Rossmann MG. Proc Natl Acad Sci U S A 117 8890-8899 (2020)
  159. Deciphering the dark proteome of Chikungunya virus. Singh A, Kumar A, Yadav R, Uversky VN, Giri R. Sci Rep 8 5822 (2018)
  160. Discovery of novel multi-target indole-based derivatives as potent and selective inhibitors of chikungunya virus replication. Scuotto M, Abdelnabi R, Collarile S, Schiraldi C, Delang L, Massa A, Ferla S, Brancale A, Leyssen P, Neyts J, Filosa R. Bioorg. Med. Chem. 25 327-337 (2017)
  161. Endemic chikungunya fever in Kenyan children: a prospective cohort study. Nyamwaya DK, Otiende M, Omuoyo DO, Githinji G, Karanja HK, Gitonga JN, R de Laurent Z, Otieno JR, Sang R, Kamau E, Cheruiyot S, Otieno E, Agoti CN, Bejon P, Thumbi SM, Warimwe GM. BMC Infect Dis 21 186 (2021)
  162. Evolution-Driven Attenuation of Alphaviruses Highlights Key Glycoprotein Determinants Regulating Viral Infectivity and Dissemination. Noval MG, Rodriguez-Rodriguez BA, Rangel MV, Stapleford KA. Cell Rep 28 460-471.e5 (2019)
  163. Identification of a specific region in the e1 fusion protein involved in zinc inhibition of semliki forest virus fusion. Liu CY, Kielian M. J. Virol. 86 3588-3594 (2012)
  164. Mutations in the E2 Glycoprotein and the 3' Untranslated Region Enhance Chikungunya Virus Virulence in Mice. Hawman DW, Carpentier KS, Fox JM, May NA, Sanders W, Montgomery SA, Moorman NJ, Diamond MS, Morrison TE. J. Virol. 91 (2017)
  165. Neutralizing antibodies protect mice against Venezuelan equine encephalitis virus aerosol challenge. Kafai NM, Williamson LE, Binshtein E, Sukupolvi-Petty S, Gardner CL, Liu J, Mackin S, Kim AS, Kose N, Carnahan RH, Jung A, Droit L, Reed DS, Handley SA, Klimstra WB, Crowe JE, Diamond MS. J Exp Med 219 e20212532 (2022)
  166. Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein. Kim AS, Austin SK, Gardner CL, Zuiani A, Reed DS, Trobaugh DW, Sun C, Basore K, Williamson LE, Crowe JE, Slifka MK, Fremont DH, Klimstra WB, Diamond MS. Nat Microbiol 4 187-197 (2019)
  167. Structure and interaction with lipid membrane models of Semliki Forest virus fusion peptide. Agopian A, Quetin M, Castano S. Biochim Biophys Acta 1858 2671-2680 (2016)
  168. Structure-Function Dissection of Pseudorabies Virus Glycoprotein B Fusion Loops. Vallbracht M, Brun D, Tassinari M, Vaney MC, Pehau-Arnaudet G, Guardado-Calvo P, Haouz A, Klupp BG, Mettenleiter TC, Rey FA, Backovic M. J. Virol. 92 (2018)
  169. The CD147 Protein Complex Is Involved in Entry of Chikungunya Virus and Related Alphaviruses in Human Cells. De Caluwé L, Coppens S, Vereecken K, Daled S, Dhaenens M, Van Ostade X, Deforce D, Ariën KK, Bartholomeeusen K. Front Microbiol 12 615165 (2021)
  170. The evolution of chikungunya virus circulating in Indonesia: Sequence analysis of the orf2 gene encoding the viral structural proteins. Hakim MS, Annisa L, Aman AT. Int Microbiol 26 781-790 (2023)
  171. Understanding the interactability of chikungunya virus proteins via molecular recognition feature analysis. Singh A, Kumar A, Uversky VN, Giri R. RSC Adv 8 27293-27303 (2018)
  172. A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus. Allen ER, Krumm SA, Raghwani J, Halldorsson S, Elliott A, Graham VA, Koudriakova E, Harlos K, Wright D, Warimwe GM, Brennan B, Huiskonen JT, Dowall SD, Elliott RM, Pybus OG, Burton DR, Hewson R, Doores KJ, Bowden TA. Cell Rep 25 3750-3758.e4 (2018)
  173. Chikungunya virus cell-to-cell transmission is mediated by intercellular extensions in vitro and in vivo. Yin P, Davenport BJ, Wan JJ, Kim AS, Diamond MS, Ware BC, Tong K, Couderc T, Lecuit M, Lai JR, Morrison TE, Kielian M. Nat Microbiol 8 1653-1667 (2023)
  174. Chikungunya-vesicular stomatitis chimeric virus targets and eliminates brain tumors. Zhang X, Mao G, van den Pol AN. Virology 522 244-259 (2018)
  175. Construction and organization of a BSL-3 cryo-electron microscopy laboratory at UTMB. Sherman MB, Trujillo J, Leahy I, Razmus D, Dehate R, Lorcheim P, Czarneski MA, Zimmerman D, Newton JT, Haddow AD, Weaver SC. J. Struct. Biol. 181 223-233 (2013)
  176. Highly potent multivalent VHH antibodies against Chikungunya isolated from an alpaca naïve phage display library. Li Q, Zhang F, Lu Y, Hu H, Wang J, Guo C, Deng Q, Liao C, Wu Q, Hu T, Chen Z, Lu J. J Nanobiotechnology 20 231 (2022)
  177. Host ESCRT factors are recruited during chikungunya virus infection and are required for the intracellular viral replication cycle. Torii S, Orba Y, Sasaki M, Tabata K, Wada Y, Carr M, Hobson-Peters J, Hall RA, Takada A, Fukuhara T, Matsuura Y, Hall WW, Sawa H. J Biol Chem 295 7941-7957 (2020)
  178. Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease. Powell LA, Fox JM, Kose N, Kim AS, Majedi M, Bombardi R, Carnahan RH, Slaughter JC, Morrison TE, Diamond MS, Crowe JE. PLoS Pathog 16 e1008517 (2020)
  179. Implication for alphavirus host-cell entry and assembly indicated by a 3.5Å resolution cryo-EM structure. Chen L, Wang M, Zhu D, Sun Z, Ma J, Wang J, Kong L, Wang S, Liu Z, Wei L, He Y, Wang J, Zhang X. Nat Commun 9 5326 (2018)
  180. In vitro and in vivo efficacy of anti-chikungunya virus monoclonal antibodies produced in wild-type and glycoengineered Nicotiana benthamiana plants. Hurtado J, Acharya D, Lai H, Sun H, Kallolimath S, Steinkellner H, Bai F, Chen Q. Plant Biotechnol. J. 18 266-273 (2020)
  181. Inhibition of Chikungunya Virus Infection by 4-Hydroxy-1-Methyl-3-(3-morpholinopropanoyl)quinoline-2(1H)-one (QVIR) Targeting nsP2 and E2 Proteins. Islamuddin M, Afzal O, Khan WH, Hisamuddin M, Altamimi ASA, Husain I, Kato K, Alamri MA, Parveen S. ACS Omega 6 9791-9803 (2021)
  182. Investigating host-virus interaction mechanism and phylogenetic analysis of viral proteins involved in the pathogenesis. Naqvi AAT, Anjum F, Shafie A, Badar S, Elasbali AM, Yadav DK, Hassan MI. PLoS One 16 e0261497 (2021)
  183. Near-germline human monoclonal antibodies neutralize and protect against multiple arthritogenic alphaviruses. Malonis RJ, Earnest JT, Kim AS, Angeliadis M, Holtsberg FW, Aman MJ, Jangra RK, Chandran K, Daily JP, Diamond MS, Kielian M, Lai JR. Proc Natl Acad Sci U S A 118 e2100104118 (2021)
  184. Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity. Earnest JT, Basore K, Roy V, Bailey AL, Wang D, Alter G, Fremont DH, Diamond MS. J. Exp. Med. 216 2282-2301 (2019)
  185. Potent Antibody Protection against an Emerging Alphavirus Threat. Kielian M, Saphire EO. Cell 163 1053-1054 (2015)
  186. Potential entry inhibitors of the envelope protein (E2) of Chikungunya virus: in silico structural modeling, docking and molecular dynamic studies. Deeba F, Malik MZ, Naqvi IH, Haider MSH, Shafat Z, Sinha P, Ishrat R, Ahmed A, Parveen S. Virusdisease 28 39-49 (2017)
  187. Radicicol Inhibits Chikungunya Virus Replication by Targeting Nonstructural Protein 2. Nam S, Ga YJ, Lee JY, Hwang WY, Jung E, Shin JS, Chen W, Choi G, Zhou B, Yeh JY, Go YY. Antimicrob Agents Chemother 65 e0013521 (2021)
  188. Selective transduction of astrocytic and neuronal CNS subpopulations by lentiviral vectors pseudotyped with Chikungunya virus envelope. Eleftheriadou I, Dieringer M, Poh XY, Sanchez-Garrido J, Gao Y, Sgourou A, Simmons LE, Mazarakis ND. Biomaterials 123 1-14 (2017)
  189. Seroprevalence of Getah virus in Pigs in Eastern China Determined with a Recombinant E2 Protein-Based Indirect ELISA. Sun Q, Xie Y, Guan Z, Zhang Y, Li Y, Yang Y, Zhang J, Li Z, Qiu Y, Li B, Liu K, Shao D, Wang J, Ma Z, Wei J, Li P. Viruses 14 2173 (2022)
  190. Structures of the Hepaci-, Pegi-, and Pestiviruses envelope proteins suggest a novel membrane fusion mechanism. Oliver MR, Toon K, Lewis CB, Devlin S, Gifford RJ, Grove J. PLoS Biol 21 e3002174 (2023)
  191. Suramin Inhibits Chikungunya Virus Replication by Interacting with Virions and Blocking the Early Steps of Infection. Albulescu IC, White-Scholten L, Tas A, Hoornweg TE, Ferla S, Kovacikova K, Smit JM, Brancale A, Snijder EJ, van Hemert MJ. Viruses 12 (2020)
  192. The E2 glycoprotein holds key residues for Mayaro virus adaptation to the urban Aedes aegypti mosquito. Cereghino C, Roesch F, Carrau L, Hardy A, Ribeiro-Filho HV, Henrion-Lacritick A, Koh C, Marano JM, Bates TA, Rai P, Chuong C, Akter S, Vallet T, Blanc H, Elliott TJ, Brown AM, Michalak P, LeRoith T, Bloom JD, Marques RE, Saleh MC, Vignuzzi M, Weger-Lucarelli J. PLoS Pathog 19 e1010491 (2023)
  193. The Hantavirus Surface Glycoprotein Lattice and Its Fusion Control Mechanism. Serris A, Stass R, Bignon EA, Muena NA, Manuguerra JC, Jangra RK, Li S, Chandran K, Tischler ND, Huiskonen JT, Rey FA, Guardado-Calvo P. Cell 183 442-456.e16 (2020)
  194. Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress. Williamson LE, Reeder KM, Bailey K, Tran MH, Roy V, Fouch ME, Kose N, Trivette A, Nargi RS, Winkler ES, Kim AS, Gainza C, Rodriguez J, Armstrong E, Sutton RE, Reidy J, Carnahan RH, McDonald WH, Schoeder CT, Klimstra WB, Davidson E, Doranz BJ, Alter G, Meiler J, Schey KL, Julander JG, Diamond MS, Crowe JE. Cell 184 4430-4446.e22 (2021)
  195. Vaccine elicitation and structural basis for antibody protection against alphaviruses. Sutton MS, Pletnev S, Callahan V, Ko S, Tsybovsky Y, Bylund T, Casner RG, Cerutti G, Gardner CL, Guirguis V, Verardi R, Zhang B, Ambrozak D, Beddall M, Lei H, Yang ES, Liu T, Henry AR, Rawi R, Schön A, Schramm CA, Shen CH, Shi W, Stephens T, Yang Y, Florez MB, Ledgerwood JE, Burke CW, Shapiro L, Fox JM, Kwong PD, Roederer M. Cell 186 2672-2689.e25 (2023)
  196. In-silico prediction of novel drug-target complex of nsp3 of CHIKV through molecular dynamic simulation. Kumar D, Meena MK, Kumari K, Patel R, Jayaraj A, Singh P. Heliyon 6 e04720 (2020)
  197. A Bivalent Trans-Amplifying RNA Vaccine Candidate Induces Potent Chikungunya and Ross River Virus Specific Immune Responses. Schmidt C, Hastert FD, Gerbeth J, Beissert T, Sahin U, Perkovic M, Schnierle BS. Vaccines (Basel) 10 1374 (2022)
  198. A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans. Raju S, Adams LJ, Earnest JT, Warfield K, Vang L, Crowe JE, Fremont DH, Diamond MS. Sci Transl Med 15 eade8273 (2023)
  199. A cross-reactive antibody protects against Ross River virus musculoskeletal disease despite rapid neutralization escape in mice. Fox JM, Huang L, Tahan S, Powell LA, Crowe JE, Wang D, Diamond MS. PLoS Pathog 16 e1008743 (2020)
  200. A high-throughput screening assay to identify inhibitory antibodies targeting alphavirus release. Ramjag A, Cutrone S, Lu K, Crasto C, Jin J, Bakkour S, Carrington CVF, Simmons G. Virol J 19 170 (2022)
  201. An Evolutionary Insertion in the Mxra8 Receptor-Binding Site Confers Resistance to Alphavirus Infection and Pathogenesis. Kim AS, Zimmerman O, Fox JM, Nelson CA, Basore K, Zhang R, Durnell L, Desai C, Bullock C, Deem SL, Oppenheimer J, Shapiro B, Wang T, Cherry S, Coyne CB, Handley SA, Landis MJ, Fremont DH, Diamond MS. Cell Host Microbe 27 428-440.e9 (2020)
  202. An attenuated replication-competent chikungunya virus with a fluorescently tagged envelope. Jin J, Sherman MB, Chafets D, Dinglasan N, Lu K, Lee TH, Carlson LA, Muench MO, Simmons G. PLoS Negl Trop Dis 12 e0006693 (2018)
  203. Analytical and Clinical Evaluation of a TaqMan Real-Time PCR Assay for the Detection of Chikungunya Virus. Andrew A, Citartan M, Wong KA, Tang TH, Magdline Sia Henry S, Ch'ng ES. Microbiol Spectr 11 e0008823 (2023)
  204. Cathepsin B Protease Facilitates Chikungunya Virus Envelope Protein-Mediated Infection via Endocytosis or Macropinocytosis. Izumida M, Hayashi H, Tanaka A, Kubo Y. Viruses 12 (2020)
  205. Characterization of a Chikungunya virus strain isolated from banked patients' sera. Chalaem P, Chusri S, Fernandez S, Chotigeat W, Anguita J, Pal U, Promnares K. Virol. J. 13 150 (2016)
  206. Characterization of the RNA-dependent RNA polymerase from Chikungunya virus and discovery of a novel ligand as a potential drug candidate. Freire MCLC, Basso LGM, Mendes LFS, Mesquita NCMR, Mottin M, Fernandes RS, Policastro LR, Godoy AS, Santos IA, Ruiz UEA, Caruso IP, Sousa BKP, Jardim ACG, Almeida FCL, Gil LHVG, Andrade CH, Oliva G. Sci Rep 12 10601 (2022)
  207. Chikungunya Virus E2 Structural Protein B-Cell Epitopes Analysis. Silva JPDC, Cunha MDP, Pour SZ, Hering VR, Neto DFL, Zanotto PMA. Viruses 14 1839 (2022)
  208. Chikungunya Virus' High Genomic Plasticity Enables Rapid Adaptation to Restrictive A549 Cells. De Caluwé L, Heyndrickx L, Coppens S, Vereecken K, Quiñones-Mateu ME, Merits A, Ariën KK, Bartholomeeusen K. Viruses 14 282 (2022)
  209. Chikungunya outbreak in Africa: a review of the literature. Chinedu Eneh S, Uwishema O, Nazir A, El Jurdi E, Faith Olanrewaju O, Abbass Z, Mustapha Jolayemi M, Mina N, Kseiry L, Onyeaka H. Ann Med Surg (Lond) 85 3545-3552 (2023)
  210. Chikungunya virus entry and infectivity is primarily facilitated through cell line dependent attachment factors in mammalian and mosquito cells. Reyes Ballista JM, Miazgowicz KL, Acciani MD, Jimenez AR, Belloli RS, Havranek KE, Brindley MA. Front Cell Dev Biol 11 1085913 (2023)
  211. Chikungunya virus: genomic microevolution in Eastern India and its in-silico epitope prediction. Dutta SK, Bhattacharya T, Tripathi A. 3 Biotech 8 318 (2018)
  212. Chikungunya-specific IgG and neutralizing antibody responses in natural infection of Chikungunya virus in children from India. Verma A, Nayak K, Chandele A, Singla M, Ratageri VH, Lodha R, Kabra SK, Murali-Krishna K, Ray P. Arch Virol 166 1913-1920 (2021)
  213. Computer-Aided Design, Synthesis, and Antiviral Evaluation of Novel Acrylamides as Potential Inhibitors of E3-E2-E1 Glycoproteins Complex from Chikungunya Virus. Passos GFS, Gomes MGM, Aquino TM, Araújo-Júnior JX, Souza SJM, Cavalcante JPM, Santos ECD, Bassi ÊJ, Silva-Júnior EFD. Pharmaceuticals (Basel) 13 (2020)
  214. Construction and Evaluation of Recombinant Adenovirus Candidate Vaccines for Chikungunya Virus. Cao L, Wang W, Sun W, Zhang J, Han J, Xie C, Ha Z, Xie Y, Zhang H, Jin N, Lu H. Viruses 14 1779 (2022)
  215. Cooperative Chikungunya Virus Membrane Fusion and Its Substoichiometric Inhibition by CHK-152 Antibody. Blijleven JS, Bouma EM, van Duijl-Richter MKS, Smit JM, van Oijen AM. Viruses 14 270 (2022)
  216. Cryo-EM Structures of Eastern Equine Encephalitis Virus Reveal Mechanisms of Virus Disassembly and Antibody Neutralization. Hasan SS, Sun C, Kim AS, Watanabe Y, Chen CL, Klose T, Buda G, Crispin M, Diamond MS, Klimstra WB, Rossmann MG. Cell Rep 25 3136-3147.e5 (2018)
  217. Cryo-EM structures of alphavirus conformational intermediates in low pH-triggered prefusion states. Chen CL, Klose T, Sun C, Kim AS, Buda G, Rossmann MG, Diamond MS, Klimstra WB, Kuhn RJ. Proc Natl Acad Sci U S A 119 e2114119119 (2022)
  218. Development and application of an indirect ELISA for detecting equine IgG antibodies against Getah virus with recombinant E2 domain protein. Qiu X, Cao X, Shi N, Zhang H, Zhu X, Gao Y, Mai Z, Jin N, Lu H. Front Microbiol 13 1029444 (2022)
  219. Development of a Specific CHIKV-E2 Monoclonal Antibody for Chikungunya Diagnosis. Kim J, Yang J, Kim YB, Lee HJ, Kim S, Poo H. Virol Sin 34 563-571 (2019)
  220. Development of a neutralization assay based on the pseudotyped chikungunya virus of a Korean isolate. Chung WC, Hwang KY, Kang SJ, Kim JO, Song MJ. J Microbiol 58 46-53 (2020)
  221. Development of an E2 ELISA Methodology to Assess Chikungunya Seroprevalence in Patients from an Endemic Region of Mexico. Kim YC, López-Camacho C, Garcia-Larragoiti N, Cano-Mendez A, Hernandez-Flores KG, Domínguez-Alemán CA, Mar MA, Vivanco-Cid H, Viveros-Sandoval ME, Reyes-Sandoval A. Viruses 11 (2019)
  222. Discrete viral E2 lysine residues and scavenger receptor MARCO are required for clearance of circulating alphaviruses. Carpentier KS, Davenport BJ, Haist KC, McCarthy MK, May NA, Robison A, Ruckert C, Ebel GD, Morrison TE. Elife 8 (2019)
  223. Drug repurposing approach against chikungunya virus: an in vitro and in silico study. Kasabe B, Ahire G, Patil P, Punekar M, Davuluri KS, Kakade M, Alagarasu K, Parashar D, Cherian S. Front Cell Infect Microbiol 13 1132538 (2023)
  224. Emergence of a novel chikungunya virus strain bearing the E1:V80A substitution, out of the Mombasa, Kenya 2017-2018 outbreak. Eyase F, Langat S, Berry IM, Mulwa F, Nyunja A, Mutisya J, Owaka S, Limbaso S, Ofula V, Koka H, Koskei E, Lutomiah J, Jarman RG, Sang R. PLoS One 15 e0241754 (2020)
  225. Entry receptor LDLRAD3 is required for Venezuelan equine encephalitis virus peripheral infection and neurotropism leading to pathogenesis in mice. Kafai NM, Janova H, Cain MD, Alippe Y, Muraro S, Sariol A, Elam-Noll M, Klein RS, Diamond MS. Cell Rep 42 112946 (2023)
  226. Evaluation of the Antiviral Potential of Halogenated Dihydrorugosaflavonoids and Molecular Modeling with nsP3 Protein of Chikungunya Virus (CHIKV). Puranik NV, Rani R, Singh VA, Tomar S, Puntambekar HM, Srivastava P. ACS Omega 4 20335-20345 (2019)
  227. Evidence of chikungunya virus infections among febrile patients at three secondary health facilities in the Ashanti and the Bono Regions of Ghana. Adusei JA, Narkwa PW, Owusu M, Domfeh SA, Alhassan M, Appau E, Salam A, Mutocheluh M. PLoS Negl Trop Dis 15 e0009735 (2021)
  228. Evolution and activation mechanism of the flavivirus class II membrane-fusion machinery. Vaney MC, Dellarole M, Duquerroy S, Medits I, Tsouchnikas G, Rouvinski A, England P, Stiasny K, Heinz FX, Rey FA. Nat Commun 13 3718 (2022)
  229. Evolutionary analysis of the Chikungunya virus epidemic in Mexico reveals intra-host mutational hotspots in the E1 protein. Muñoz-Medina JE, Garcia-Knight MA, Sanchez-Flores A, Monroy-Muñoz IE, Grande R, Esbjörnsson J, Santacruz-Tinoco CE, González-Bonilla CR. PLoS ONE 13 e0209292 (2018)
  230. Expression of the Mxra8 Receptor Promotes Alphavirus Infection and Pathogenesis in Mice and Drosophila. Zhang R, Earnest JT, Kim AS, Winkler ES, Desai P, Adams LJ, Hu G, Bullock C, Gold B, Cherry S, Diamond MS. Cell Rep 28 2647-2658.e5 (2019)
  231. Expression, Purification, and Refolding of Chikungunya Virus Full-Length Envelope E2 Protein along with B-Cell and T-Cell Epitope Analyses Using Immuno-Informatics Approaches. Shukla M, Chandley P, Tapryal S, Kumar N, Mukherjee SP, Rohatgi S. ACS Omega 7 3491-3513 (2022)
  232. Fatal Human Infection with Evidence of Intrahost Variation of Eastern Equine Encephalitis Virus, Alabama, USA, 2019. Hughes HR, Velez JO, Davis EH, Laven J, Gould CV, Panella AJ, Lambert AJ, Staples JE, Brault AC. Emerg Infect Dis 27 1886-1892 (2021)
  233. Generation of Multiple Arbovirus-like Particles Using a Rapid Recombinant Vaccinia Virus Expression Platform. Wang Y, Griffiths A, Brackney DE, Verardi PH. Pathogens 11 1505 (2022)
  234. Genetic Variability of Chikungunya Virus in Southern Mexico. Galan-Huerta KA, Zomosa-Signoret VC, Vidaltamayo R, Caballero-Sosa S, Fernández-Salas I, Ramos-Jiménez J, Rivas-Estilla AM. Viruses 11 (2019)
  235. Genetic characterization of Chikungunya virus 2009 isolates from South India. Sarangan G, Nayar SA, Mani M, Sundarrajan S, Sankar S, Palani G, Selvaraj GF, Damodharan J, Muthumani K, Srikanth P. Bioinformation 14 106-112 (2018)
  236. Global transmission and evolutionary dynamics of the Chikungunya virus. Deeba F, Haider MSH, Ahmed A, Tazeen A, Faizan MI, Salam N, Hussain T, Alamery SF, Parveen S. Epidemiol Infect 148 e63 (2020)
  237. Heterologous DNA Prime- Subunit Protein Boost with Chikungunya Virus E2 Induces Neutralizing Antibodies and Cellular-Mediated Immunity. Coirada FC, Fernandes ER, Mello LR, Schuch V, Soares Campos G, Braconi CT, Boscardin SB, Santoro Rosa D. Int J Mol Sci 24 10517 (2023)
  238. Human Antibodies Protect against Aerosolized Eastern Equine Encephalitis Virus Infection. Williamson LE, Gilliland T, Yadav PK, Binshtein E, Bombardi R, Kose N, Nargi RS, Sutton RE, Durie CL, Armstrong E, Carnahan RH, Walker LM, Kim AS, Fox JM, Diamond MS, Ohi MD, Klimstra WB, Crowe JE. Cell 183 1884-1900.e23 (2020)
  239. Human monoclonal antibodies against chikungunya virus target multiple distinct epitopes in the E1 and E2 glycoproteins. Quiroz JA, Malonis RJ, Thackray LB, Cohen CA, Pallesen J, Jangra RK, Brown RS, Hofmann D, Holtsberg FW, Shulenin S, Nyakatura EK, Durnell LA, Rayannavar V, Daily JP, Ward AB, Aman MJ, Dye JM, Chandran K, Diamond MS, Kielian M, Lai JR. PLoS Pathog. 15 e1008061 (2019)
  240. In Depth Viral Diversity Analysis in Atypical Neurological and Neonatal Chikungunya Infections in Rio de Janeiro, Brazil. Torres MC, Di Maio F, Brown D, Spyer M, Nastouli E, Brasil P, Bispo de Filippis AM. Viruses 14 2006 (2022)
  241. In silico and in vitro evaluation of silibinin: a promising anti-Chikungunya agent. Dutta SK, Sengupta S, Tripathi A. In Vitro Cell Dev Biol Anim 58 255-267 (2022)
  242. In silico identification and in vitro antiviral validation of potential inhibitors against Chikungunya virus. Verma J, Hasan A, Sunil S, Subbarao N. J Comput Aided Mol Des 36 521-536 (2022)
  243. Insights into the role of the cobalt(III)-thiosemicarbazone complex as a potential inhibitor of the Chikungunya virus nsP4. Martins DOS, Souza RAC, Freire MCLC, de Moraes Roso Mesquita NC, Santos IA, de Oliveira DM, Junior NN, de Paiva REF, Harris M, Oliveira CG, Oliva G, Jardim ACG. J Biol Inorg Chem 28 101-115 (2023)
  244. Interactions involved in pH protection of the alphavirus fusion protein. Fields W, Kielian M. Virology 486 173-179 (2015)
  245. Intrinsic antiviral immunity of barrier cells revealed by an iPSC-derived blood-brain barrier cellular model. Cheng Y, Medina A, Yao Z, Basu M, Natekar JP, Lang J, Sanchez E, Nkembo MB, Xu C, Qian X, Nguyen PTT, Wen Z, Song H, Ming GL, Kumar M, Brinton MA, Li MMH, Tang H. Cell Rep 39 110885 (2022)
  246. Lineage Divergence and Vector-Specific Adaptation Have Driven Chikungunya Virus onto Multiple Adaptive Landscapes. Chen R, Plante JA, Plante KS, Yun R, Shinde D, Liu J, Haller S, Mukhopadhyay S, Weaver SC. mBio 12 e0273821 (2021)
  247. Molecular Docking Studies to Explore Potential Binding Pockets and Inhibitors for Chikungunya Virus Envelope Glycoproteins. Nguyen PTV, Yu H, Keller PA. Interdiscip Sci 10 515-524 (2018)
  248. Molecular organization and dynamics of the fusion protein Gc at the hantavirus surface. Bignon EA, Albornoz A, Guardado-Calvo P, Rey FA, Tischler ND. Elife 8 (2019)
  249. Mutation of N-glycosylation Sites in Salmonid Alphavirus (SAV) Envelope Proteins Attenuate the Virus in Cell Culture. Aksnes I, Markussen T, Braaen S, Rimstad E. Viruses 12 (2020)
  250. Mutations at the Alphavirus E1'-E2 Interdimer Interface Have Host-Specific Phenotypes. Ren SC, Qazi SA, Towell B, Wang JC, Mukhopadhyay S. J Virol 96 e0214921 (2022)
  251. Novel Molecular Signatures of Chikungunya Virus in Puerto Rico. López P, De Jesús O, García-Justiniano J, Rivera-Amill V. P R Health Sci J 38 27-32 (2019)
  252. Organisation of the orthobunyavirus tripodal spike and the structural changes induced by low pH and K+ during entry. Hover S, Charlton FW, Hellert J, Swanson JJ, Mankouri J, Barr JN, Fontana J. Nat Commun 14 5885 (2023)
  253. Peptide aptamer-based time-resolved fluoroimmunoassay for CHIKV diagnosis. Liu T, Gao C, Wang J, Song J, Chen X, Chen H, Zhao X, Tang H, Gu D. Virol J 20 166 (2023)
  254. Positive-strand RNA viruses-a Keystone Symposia report. Cable J, Denison MR, Kielian M, Jackson WT, Bartenschlager R, Ahola T, Mukhopadhyay S, Fremont DH, Kuhn RJ, Shannon A, Frazier MN, Yuen KY, Coyne CB, Wolthers KC, Ming GL, Guenther CS, Moshiri J, Best SM, Schoggins JW, Jurado KA, Ebel GD, Schäfer A, Ng LFP, Kikkert M, Sette A, Harris E, Wing PAC, Eggenberger J, Krishnamurthy SR, Mah MG, Meganck RM, Chung D, Maurer-Stroh S, Andino R, Korber B, Perlman S, Shi PY, Bárcena M, Aicher SM, Vu MN, Kenney DJ, Lindenbach BD, Nishida Y, Rénia L, Williams EP. Ann N Y Acad Sci 1521 46-66 (2023)
  255. Prediction of MAYV peptide antigens for immunodiagnostic tests by immunoinformatics and molecular dynamics simulations. Rodrigues RL, Menezes GL, Saivish MV, Costa VGD, Pereira M, Moreli ML, Silva RAD. Sci Rep 9 13339 (2019)
  256. Recombinant Baculovirus: A Flexible Drug Screening Platform for Chikungunya Virus. Varikkodan MM, Chen CC, Wu TY. Int J Mol Sci 22 7891 (2021)
  257. Requirement of a functional ion channel for Sindbis virus glycoprotein transport, CPV-II formation, and efficient virus budding. Elmasri Z, Negi V, Kuhn RJ, Jose J. PLoS Pathog 18 e1010892 (2022)
  258. Role of the vacuolar ATPase in the Alphavirus replication cycle. Schuchman RM, Vancini R, Piper A, Breuer D, Ribeiro M, Ferreira D, Magliocca J, Emmerich V, Hernandez R, Brown DT. Heliyon 4 e00701 (2018)
  259. STT3A-mediated viral N-glycosylation underlies the tumor selectivity of oncolytic virus M1. Song D, Jia X, Gao Y, Xiao T, Dan J, Shen R, Cai J, Liang J, Zhu W, Hu J, Yan G, Zhang Q, Lin Y. Oncogene 42 3575-3588 (2023)
  260. Species-specific MARCO-alphavirus interactions dictate chikungunya virus viremia. Li FS, Carpentier KS, Hawman DW, Lucas CJ, Ander SE, Feldmann H, Morrison TE. Cell Rep 42 112418 (2023)
  261. Spread of a Novel Indian Ocean Lineage Carrying E1-K211E/E2-V264A of Chikungunya Virus East/Central/South African Genotype across the Indian Subcontinent, Southeast Asia, and Eastern Africa. Phadungsombat J, Imad HA, Nakayama EE, Leaungwutiwong P, Ramasoota P, Nguitragool W, Matsee W, Piyaphanee W, Shioda T. Microorganisms 10 354 (2022)
  262. Structural Insights into Alphavirus Assembly Revealed by the Cryo-EM Structure of Getah Virus. Wang M, Sun Z, Cui C, Wang S, Yang D, Shi Z, Wei X, Wang P, Sun W, Zhu J, Li J, Du B, Liu Z, Wei L, Liu C, He X, Wang X, Zhang X, Wang J. Viruses 14 327 (2022)
  263. Structural constraints link differences in neutralization potency of human anti-Eastern equine encephalitis virus monoclonal antibodies. Williamson LE, Bandyopadhyay A, Bailey K, Sirohi D, Klose T, Julander JG, Kuhn RJ, Crowe JE. Proc Natl Acad Sci U S A 120 e2213690120 (2023)
  264. Structure of infective Getah virus at 2.8 Å resolution determined by cryo-electron microscopy. Wang A, Zhou F, Liu C, Gao D, Qi R, Yin Y, Liu S, Gao Y, Fu L, Xia Y, Xu Y, Wang C, Liu Z. Cell Discov 8 12 (2022)
  265. Studies on the antiviral activity of chebulinic acid against dengue and chikungunya viruses and in silico investigation of its mechanism of inhibition. Thomas N, Patil P, Sharma A, Kumar S, Singh VK, Alagarasu K, Parashar D, Tapryal S. Sci Rep 12 10397 (2022)
  266. Taxonomic patterns in the zoonotic potential of mammalian viruses. Washburne AD, Crowley DE, Becker DJ, Olival KJ, Taylor M, Munster VJ, Plowright RK. PeerJ 6 e5979 (2018)
  267. The 8-bromobaicalein alleviated chikungunya-induced musculoskeletal inflammation and reduced the viral load in healthy adult mice. Cao V, Loeanurit N, Hengphasatporn K, Hairani R, Wacharachaisurapol N, Prompila N, Wittayalertpanya S, Shigeta Y, Khotavivattana T, Chavasiri W, Boonyasuppayakorn S. Emerg Microbes Infect 12 2270074 (2023)
  268. The Alphavirus E2 Membrane-Proximal Domain Impacts Capsid Interaction and Glycoprotein Lattice Formation. Byrd EA, Kielian M. J. Virol. 93 (2019)
  269. The protein disulfide isomerase inhibitor 3-methyltoxoflavin inhibits Chikungunya virus. Puhl AC, Fernandes RS, Godoy AS, Gil LHVG, Oliva G, Ekins S. Bioorg Med Chem 83 117239 (2023)
  270. The utilization of advance telemetry to investigate critical physiological parameters including electroencephalography in cynomolgus macaques following aerosol challenge with eastern equine encephalitis virus. Trefry JC, Rossi FD, Accardi MV, Dorsey BL, Sprague TR, Wollen-Roberts SE, Shamblin JD, Kimmel AE, Glass PJ, Miller LJ, Burke CW, Cardile AP, Smith DR, Bavari S, Authier S, Pratt WD, Pitt ML, Nasar F. PLoS Negl Trop Dis 15 e0009424 (2021)
  271. Two Conserved Phenylalanine Residues in the E1 Fusion Loop of Alphaviruses Are Essential for Viral Infectivity. Lucas CJ, Davenport BJ, Carpentier KS, Tinega AN, Morrison TE. J Virol 96 e0006422 (2022)
  272. Use of Nanotrap particles for the capture and enrichment of Zika, chikungunya and dengue viruses in urine. Lin SC, Carey BD, Callahan V, Lee JH, Bracci N, Patnaik A, Smith AK, Narayanan A, Lepene B, Kehn-Hall K. PLoS ONE 15 e0227058 (2020)
  273. Vertebrate-class-specific binding modes of the alphavirus receptor MXRA8. Zimmerman O, Zimmerman MI, Raju S, Nelson CA, Errico JM, Madden EA, Holmes AC, Hassan AO, VanBlargan LA, Kim AS, Adams LJ, Basore K, Whitener BM, Palakurty S, Davis-Adams HG, Sun C, Gilliland T, Earnest JT, Ma H, Ebel GD, Zmasek C, Scheuermann RH, Klimstra WB, Fremont DH, Diamond MS. Cell 186 4818-4833.e25 (2023)
  274. Virtual screening of inhibitors against Envelope glycoprotein of Chikungunya Virus: a drug repositioning approach. Agarwal G, Gupta S, Gabrani R, Gupta A, Chaudhary VK, Gupta V. Bioinformation 15 439-447 (2019)
  275. Visualization of conformational changes and membrane remodeling leading to genome delivery by viral class-II fusion machinery. Mangala Prasad V, Blijleven JS, Smit JM, Lee KK. Nat Commun 13 4772 (2022)


Related citations provided by authors (1)

  1. Mapping the structure and function of the E1 and E2 glycoproteins in alphaviruses.. Mukhopadhyay S, Zhang W, Gabler S, Chipman PR, Strauss EG, Strauss JH, Baker TS, Kuhn RJ, Rossmann MG Structure 14 63-73 (2006)